{{locationDetails}}
Aspeya, owned by Philip Morris International, operates independently and utilizes Fertin Pharma's oral technology platform. Fertin Pharma, a wholly owned subsidiary of Aspeya, is a CDMO that develops and manufactures innovative oral and intra-oral delivery systems.
BiomedVC is a leading Swiss early-stage venture capital fund at the center of European biotech. We focus on finding great science and building promising startups to deliver better medicines for patients.
Curie.Bio is a $1.2B VC founded to discover and develop important new medicines. We do that by investing directly into existing companies, creating focused spinouts, and helping founders build companies from scratch. Our team of >80 full-time drug hunters provides hands on support to founders.
At CxO, we drive biotech startups toward growth by optimizing resource management and operational efficiency. As partners, we empower firms to innovate and scale. Our veteran team offers strategic insights to accelerate timelines, optimize ROI, and enhance workflows, ensuring client success
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug manufacturing and digital health investment.
DIAMANTE is a boutique business and management consulting company dedicated to biotech/ pharma clients, diagnostics companies and investors in healthcare. We support companies to streamline product design and development, and work with investors to accelerate and de-risk their selected assets.
Holding, management consulting & strategy advisory focused on biotech, medtech, nutraceuticals and health services. Our strong knowledge of international competitive and synergistic landscape and our large network of strategic partners help our clients to expand into new jurisdictions and markets.
Our mission is to propel healthcare forward by investing in solutions that promise to enhance global well-being, driven by a team whose core strengths lie in strategic investment, scientific analysis, and an acute understanding of healthcare market dynamics.
Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. We invest in companies in Switzerland or abroad that are active in the field of life sciences. We value strong founding teams and high-quality science.
Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.
Pureos Bioventures is a venture capital fund to exclusively invest in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. For more information: www.pureosbio.com
Rambam AG is a Swiss-based venture studio and accelerator platform for breakthrough drug discovery and development. Our portfolio of companies and programs is supported by a core group of seasoned industrial experts, PMs and dedicated functional experts from Switzerland, Portugal, Germany and the US.
SENN is a real estate company and as such is developing the MAIN CAMPUS which is Switzerland’s largest life‑sciences campus in Allschwil. We’re developing five sustainable buildings by 2029 with flexible labs, offices and coworking spaces designed to accelerate ideas within a vibrant ecosystem.
SOTIO is a biotech company building a diverse portfolio of oncology products through its own R&D, collaborations, in-licensing, investments, M&A. SOTIO is conducting multiple Phase I to III clinical trials targeting various types of cancer and has facilities in Europe and the US.
Strategic, operational, business and finance advice to companies in the Life Sciences with focus on business planning and implementation (including strategies to secure financing, M&A and financial planning), clinical development/medical affairs and technical development/operations (CMC).
Xcube.bio invests capital, knowledge and capabilities in the European market entry of late-stage biopharmas, with the objective to create partners' own commercial footprint and revenue streams. We offer a unique value proposition that open and de-risk the European market for innovative therapies.
Xlife Sciences is a publicly listed life sciences incubator and accelerator. Xlife is focused on the value development and commercialization of promising research projects from universities and other research institutions. The goal is to bridge research and development to healthcare markets.
ADIPSE SÃ rl is a boutique IP law firm specialised in IP due diligence during financing rounds and specialised in advising early stage companies.
Our fingerprint: knowhow, network, and capital. ADYA is a Swiss Investment boutique in the life sciences sector that provides strategic consulting, C-level management and access to capital to SMEs and offers a unique service to investors clients looking for investments and asset allocation.
Awen GmbH builds innovative life science companies encompassing strategy, founding, financing, and partnering.
Binz Biotech Consulting GmbH offers life science management consultancy. Its mission is to support the success of your business. The consulting portfolio of Binz Biotech Consulting is based on hands-on biotech company-building experience. Consulting is provided for biotech, pharma as well as VCs.
Based in Basel, BioMedPartners is a leading, independent European venture capital firm, that acts frequently as lead-or co-lead investor providing private equity to early-to mid-stage life sciences companies.
The group, offering state-of-the-art regenerative medicine solutions, has developed a technology platform that gave birth to therapies aiming at tissue regeneration across different applications, in order to provide pertinent and sustainable solutions leveraging the human's natural endowment.
CXIO is a Swiss non profit foundation supporting integrative medicine, as well as a vision of a more respectful and healthier world. CXIO Foundation is legally recognized as a public interest organization.
We are using ethical and representative AI technology to pioneer groundbreaking health ventures that transform health journeys, empowering communities in the global south. Our cutting-edge technology can address complex healthcare challenges and make a meaningful impact on people's lives.
Evoleen is a disruptive company builder that supports biotech & other enterprises to build, accelerate & enhance their digital health & smart medical device business. With our unique co-creation approach, we offer and share our knowledge in all relevant fields to designing and developing businesse
FONGIT (Fondation Genevoise pour l'Innovation Technologique) is Switzerland's premier innovation incubator supporting deep tech startups in Geneva since 1991. FONGIT’s 200+ startups, including Biotech, Pharma,  Medtech, diagnostics & digital health, have received CHF 1+ Bn of private investment.
Innosuisse is the Swiss Agency for Innovation Promotion. We promote science-based innovation in the interest of business and society, thereby strengthening the competitiveness of small and medium-sized enterprises in Switzerland.
KYBORA is a global advisory/investment bank providing M&A, licensing, fundraising and strategic consulting services to the global biopharma industry. With offices in the US, Europe and China, and a direct presence in all other key markets, KYBORA offers unparalleled global reach and local knowledge.
Livenity merges the best of three different worlds – it is a business incubator, a venture capital advisor, and a market development agency. Our mission is the development and marketing of visionary technologies in Germany, Austria, and Switzerland.
Consulting company in health care, medical devices and cosmeceuticals.
Metellus is a private investment office, specialised in direct investments in technology and life sciences. Metellus takes an active ownership role to enhance value creation and is actively involved in the management of a diverse portfolio of investments in private equity and venture capital.
A Zurich-based corporate finance firm committed to advancing the life science field through advisory and capital raise.
OCCIDENT invests in deep tech start-ups focusing on spin-offs from scientific research that address societal challenges. As an owner-managed venture capital investor, we support life sciences and industrial tech start-ups from the seed stage onwards, investing own money long-term.
Founded in 2006, Redalpine is a leading European Venture Capital investor based in Switzerland with offices in Zurich and Berlin. The fund has more than CHF 1bn in Assets under Management and invests in ICT and Life Sciences, with a highly disciplined and sector-agnostic approach.
The Venture Kick philanthropic initiative provides up to CHF 150k in seed funding to Swiss startups and offers a well-structured entrepreneurial path toward building a winning business. Winners are eligible for a CHF 850k investment from the Kickfund and an additional InnoBooster grant of CHF 150k.
Our free programs help startups close financing and accelerate global business growth. Courses include Venture Kick; the Venture Leaders life sciences roadshow to Boston; and on behalf of the government, Innosuisse training – 5 days focusing on biotech business creation (Basel) & growth (Lugano).
Healthcare & Technology Venture Capital since 2001. We build bridges between entrepreneurs’ dreams and successful companies. We enable savvy investors to partner with the best start-up companies.
High-growth/high-risk life science journey has its psychology and contexts. With expertise beyond finance, we align Science, ROI/IRR, and Stakeholder Motivation. We provide clarity to Management and Board on Value and Readiness, supporting Financing, IPO, BD&L and Accounting/Tax-related situations
XOventure portfolio: Rigi Care, Medical Research & Health Consultation and Hawkeye-MRI AG: Making full-body MRI (60 min) with contrast possible with higher resolution and no kidney issues.